 | Up a level |
Rieger, Max J; Pabst, Thomas; Jeker, Barbara; Paul, Pamella; Bergamini, Fabio; Bühler, Marco M; Condoluci, Adalgisa; Flammer, Andreas J; Rossi, Davide; Stussi, Georg; Gerber, Bernhard; Schwotzer, Rahel (2024). Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression. (In Press). Annals of hematology Springer-Verlag 10.1007/s00277-024-05901-x
Mehl, Julian; Akhoundova, Dilara; Bacher, Ulrike; Jeker, Barbara; Rhyner Agocs, Gaëlle; Ruefer, Axel; Soltermann, Susanne; Soekler, Martin; Winkler, Annette; Daskalakis, Michael; Pabst, Thomas (2024). Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers, 16(10) MDPI AG 10.3390/cancers16101854
Messerli, Christian; Wiedemann, Gertrud; Porret, Naomi; Nagler, Michael; Seipel, Katja; Jeker, Barbara; Novak, Urban; Zeerleder, Sacha; Bacher, Ulrike; Pabst, Thomas (2023). Correlation of peripheral chimeric antigen receptor T-cell (CAR-T cell) mRNA expression levels with toxicities and outcome in patients with diffuse large B-cell lymphoma (DLBCL). Turkish journal of haematology, 40(3), pp. 187-196. Turkish Society of Haematology 10.4274/tjh.galenos.2023.2023.0136
Maechler, Melanie; Bacher, Ulrike; Daskalakis, Michael; Nilius, Henning; Nagler, Michael; Mansouri Taleghani, Behrouz; Jeker, Barbara; Pabst, Thomas (2023). Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients. Hematological oncology, 41(3), pp. 583-586. Wiley 10.1002/hon.3055
Bühler, Selina; Akhoundova, Dilara; Jeker, Barbara; Legros, Myriam; Seipel, Katja; Daskalakis, Michael; Bacher, Ulrike; Pabst, Thomas (2023). Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma. Cancers, 15(2) MDPI AG 10.3390/cancers15020430
Farag, Sarah; Bacher, Ulrike; Jeker, Barbara; Legros, Myriam; Rhyner, Gaelle; Lüthi, Jean-Marc; Schardt, Julian; Zander, Thilo; Daskalakis, Michael; Mansouri, Behrouz; Manz, Chantal; Pabst, Thomas (2022). Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. Bone marrow transplantation, 57(6), pp. 990-997. Springer Nature 10.1038/s41409-022-01681-y
Seipel, Katja; Porret, Naomi; Wiedemann, Gertrud; Jeker, Barbara; Bacher, Vera Ulrike; Pabst, Thomas (2022). sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. Current issues in molecular biology, 44(4), pp. 1463-1471. MDPI 10.3390/cimb44040098
Brechbühl, Simon; Bacher, Ulrike; Jeker, Barbara; Pabst, Thomas (2021). Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. Mediterranean journal of hematology and infectious diseases, 13(1), e2021012. Università Cattolica del Sacro Cuore 10.4084/MJHID.2021.012
Jeker, Barbara; Farag, Sarah; Mansouri Taleghani, Behrouz; Novak, Urban; Mueller, Beatrice U; Li, Qiyu; Betticher, Daniel; Luethi, Jean-Marc; Farese, Simone; Ruefer, Axel; Bacher, Ulrike; Pabst, Thomas (2020). A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients. Bone marrow transplantation, 55(10), pp. 2047-2051. Springer Nature 10.1038/s41409-020-0875-8
De Santiago de Benito, Alvaro; Jeker, Barbara; Gfeller, Eva; Porret, Naomi; Banz, Yara; Novak, Urban; Bacher, Ulrike; Pabst, Thomas (2020). Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia. Haematologica - the hematology journal, 105(1), e9-e12. Ferrata-Storti Foundation 10.3324/haematol.2019.216457
Moser, Sebastian; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Betticher, Daniel; Ruefer, Axel; Egger, Thomas; Novak, Urban; Pabst, Thomas (2019). Autologous stem cell transfusions on multiple days in patients with multiple myeloma ‐ does it matter? Hematological oncology, 37(5), pp. 649-651. Wiley 10.1002/hon.2673
Prediletto, Irene; Farag, Sarah Ahmed Ibrahim; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bregy, Rachel; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone marrow transplantation, 54(12), pp. 1923-1925. Nature Publishing Group 10.1038/s41409-019-0508-2
Fassbind, Priska; Jeker, Barbara; Müller, Beatrice Ursula; Bacher, Vera Ulrike; Zimmerli, Stefan; Endrich, Olga; Gahl, Brigitta; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). Improved survival rates of AML patients following admission to the intensive care unit. Leukemia & lymphoma, 60(10), pp. 2423-2431. Informa Healthcare 10.1080/10428194.2019.1594213
Shumilov, Evgenii; Flach, Johanna; Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Novak, Urban; Gfeller, Eva; Jeker, Barbara; Amstutz, Ursula; Pabst, Thomas; Bacher, Vera (2019). Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML. Leukemia & lymphoma, 60(10), pp. 2588-2590. Taylor & Francis 10.1080/10428194.2019.1585838
Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y
Amsler, Isabel G; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Ulrike; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Luethi, Jean-Marc; Novak, Urban; Pabst, Thomas (2019). Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. Leukemia & lymphoma, 60(2), pp. 511-514. Taylor & Francis 10.1080/10428194.2018.1473577
Jeker, Barbara; Pabst Müller, Thomas Niklaus; Novak, Urban (2019). CAR-T-Zelltherapie – eine neue Behandlungsoption. Info@Onkologie, 2019(1), pp. 18-20. Aerzteverlag medinfo AG
Shumilov, Evgenii; Flach, Johanna; Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Angelillo, Anne; Trümper, Lorenz; Fiedler, Georg Martin; Jeker, Barbara; Amstutz, Ursula; Pabst, Thomas; Bacher, Vera (2019). Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations. Hematological oncology, 37(3), pp. 319-322. Wiley 10.1002/hon.2603
Shumilov, Evgenyi; Novak, Urban; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Ulrike; Pabst, Thomas (2019). Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. HemaSphere, 3(2), e176. Wolters Kluwer Health 10.1097/HS9.0000000000000176
Schnell, Bianca R.; Seipel, Katja; Bacher, Ulrike; Jeker, Barbara; Mueller, Beatrice U.; Banz, Yara; Novak, Urban; Pabst, Thomas (2019). Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. HemaSphere, 3(2), e180. Wolters Kluwer Health 10.1097/HS9.0000000000000180
Moor, Ivana; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Mueller, Beatrice U; Keller, Heinz Peter; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst, Thomas (2018). Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. Bone marrow transplantation, 53(12), pp. 1599-1602. Nature Publishing Group 10.1038/s41409-018-0245-y
Bacher, Vera Ulrike; Porret, Naomi; Joncourt, Raphael; Sanz, Javier; Aliu, Nijas; Wiedemann, Gertrud; Jeker, Barbara; Banz Wälti, Yara; Pabst, Thomas (2018). Pitfalls in the molecular follow up of mutant acute myeloid leukemia. Haematologica - the hematology journal, 103(10), e486-e488. Ferrata-Storti Foundation 10.3324/haematol.2018.192104
Farag, Sarah Ahmed Ibrahim; Jeker, Barbara; Bacher, Vera Ulrike; Mansouri Taleghani, Behrouz; Müller, Beatrice Ursula; Novak, Urban; Pabst Müller, Thomas Niklaus (2018). Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematological oncology, 36(4), pp. 671-678. Wiley 10.1002/hon.2546
Gössi, Ursina; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Vera Ulrike; Novak, Urban; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Pabst, Thomas (2018). Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological oncology, 36(2), pp. 436-444. Wiley 10.1002/hon.2490
Jeker, Barbara; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Seipel, K; Mueller, B U; Bigler, M; Betticher, D; Luethi, J-M; Farese, S; Ruefer, A; Pabst, Thomas (2018). NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Bone marrow transplantation, 53(2), pp. 175-179. Nature Publishing Group 10.1038/bmt.2017.234
Bracht, Hendrik; Hänggi, Matthias; Jeker, Barbara; Wegmüller, Ninja; Porta, Francesca; Tüller, David; Takala, Jukka; Jakob, Stephan M (2007). Incidence of low central venous oxygen saturation during unplanned admissions in a multidisciplinary intensive care unit: an observational study. Critical care, 11(1), R2. London: BioMed Central 10.1186/cc5144
Jeker, Barbara; Daskalakis, Michael; Zeerleder, Sacha; Pabst, Thomas; Novak, Urban (January 2021). CAR T Cells: Immuntherapie mit grossem Potenzial. Onkologie & Hämatologie, 2021, pp. 16-19. Prime Public Media AG
